Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Interleukin Genetics, a genetics-focused personalized health company, and Labec Pharma, a distributor of advanced diagnostic tests, have signed a licensing agreement to permit Labec Pharma to market and sell Interleukin Genetics's heart health genetic test throughout Spain and Portugal.
Subscribe to our email newsletter
This molecular diagnostic tool helps to identify individuals at elevated risk for early heart attack. As part of the agreement, the test will be marketed by Labec Pharma and the tests will be processed at Interleukin Genetics’s Clinical Laboratory Improvement Amendments-certified laboratory in Waltham, Massachusetts.
Interleukin Genetics will receive royalties and commercial milestone payments. The Interleukin Genetics’s heart health test is currently marketed within the US under the brand name Gensona.
Lewis Bender, CEO of Interleukin Genetics, said: “We are excited about this partnership with Labec Pharma, which will allow for broader and international distribution of this important genetic test product. Our heart health genetic test can give a better understanding of a person’s overall risk for heart attack, so that individuals and their physicians can begin to take the steps necessary for lowering risk to improve health outcomes.”